The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.75
Bid: 44.00
Ask: 45.50
Change: -0.40 (-0.88%)
Spread: 1.50 (3.409%)
Open: 45.50
High: 45.10
Low: 45.10
Prev. Close: 45.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Announces GBP2 Million Subscription With Two Subscribers

Thu, 02nd Apr 2020 14:55

(Alliance News) - Avacta Group PLC on Thursday said it plans to raise GBP2 million through a 11.1 million share subscription priced at 18 pence per share with two subscribers.

Shares in Avacta were down 4.7% at 20.25 pence in London on Thursday.

The subscribers will be Clare Hughes, who is the wife of Zeus Capital co-founder Richard Hughes, and Boohoo.com co-founder Mahmud Kamani. Shareholder approval for the subscription is requirement and a general meeting notice will be sent out "shortly".

Avacta developed the Affimer platform, intended as an alternative to antibodies in diagnostics and treatment.

"The company intends to utilise the net proceeds of the subscription to continue to execute the strategy outlined last October. The company's key objectives are to enter the clinic with its first preCISION chemotherapy programme, to secure further significant drug development partnerships that help progress the company's technology platforms, and to continue to grow revenues and secure licensing partnerships for Affimer diagnostics reagents," said Avacta.

"Given the current economic climate the board have deemed it prudent to take on a small amount of additional equity capital at this time to ensure that it is in a strong position to exploit progress after the coronavirus pandemic is over," the firm added.

Having inked a collaboration and option agreement with ADC Therapeutics SA in late 2019, the firm has subsequently expanded the LG Chem Life Sciences Partnership and established a South Korean joint venture with Daewoong Pharmaceutical Co Ltd.

Avacta plans to post its results for the 17 months ended December 31 "later this quarter", having ended December with a GBP8.7 million cash balance.

At present, the firm does not foresee its revenue being "materially affected" by Covid-19 or to suffer "significant delays of more than a few weeks", though "is reliant on clinical trials proceeding in the UK by the end of the year".

"The small amount of additional capital raised through the subscription will help to ensure that the company can deliver on key milestones despite the Covid-19 pandemic," said Avacta.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2021 19:07

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

Read more
8 Mar 2021 11:06

Avacta confirms efficacy of test on variant Covid-19 strains

(Sharecast News) - Cancer therapies and diagnostics company Avacta announced on Monday that its 'AffiDX' SARS-CoV-2 rapid antigen lateral flow test detected the dominant new variants of coronavirus, known as the B117 or 'Kent', variant, and the D614G variant, as well as the original strain.

Read more
24 Feb 2021 11:45

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

TRADING UPDATES: Avacta Plans Covid Test Launch Near First Quarter End

Read more
24 Feb 2021 10:25

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

AIM WINNERS & LOSERS: Mkango Hails Pilot Plant Processing Milestone

Read more
22 Feb 2021 11:01

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

AIM WINNERS & LOSERS: Clear Leisure Surges Amid Placing, Bitcoin Plans

Read more
22 Feb 2021 09:28

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test

Read more
22 Feb 2021 08:54

Avacta clarifies reports on potential use of its Covid-19 test

(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.

Read more
22 Feb 2021 08:47

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

LONDON MARKET OPEN: European Equities Slip Amid Inflation Fears

Read more
18 Feb 2021 14:31

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

IN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000

Read more
18 Feb 2021 08:49

Avacta gets approval for first-in-human study of AVA6000

(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.

Read more
16 Feb 2021 11:31

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

AIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut

Read more
16 Feb 2021 09:48

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Avacta Shares Surge On Positive Data For Covid-19 Antigen Test

Read more
16 Feb 2021 09:38

Avacta upbeat on initial data for Covid-19 rapid test study

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.

Read more
8 Feb 2021 11:25

Avacta enters commercial partnership with Mologic

(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.

Read more
8 Feb 2021 10:46

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

AIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.